Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group
Open Access
- 9 August 2007
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 21 (11), 2258-2263
- https://doi.org/10.1038/sj.leu.2404903
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology GroupBlood, 2006
- Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study GroupBlood, 2006
- Treatment of Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2006
- Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantationBlood, 2004
- Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal regionThe Lancet, 2002
- Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987–1999British Journal of Haematology, 2002
- High Survival Rate in Infant Acute Leukemia Treated With Early High-Dose Chemotherapy and Stem-Cell SupportJournal of Clinical Oncology, 2000
- Intensified therapy for infants with acute lymphoblastic leukemiaCancer, 1997
- Therapeutic Trial for Infant Acute Lymphoblastic Leukemia: The Pediatric Oncology Group Experience (POG 8493)Journal of Pediatric Hematology/Oncology, 1997
- 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia.Journal of Clinical Oncology, 1994